Wealthcare Advisory Partners LLC Acurx Pharmaceuticals, Inc. Transaction History
Wealthcare Advisory Partners LLC
- $4.19 Billion
- Q2 2025
A detailed history of Wealthcare Advisory Partners LLC transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealthcare Advisory Partners LLC holds 11,538 shares of ACXP stock, worth $5,538. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,538Holding current value
$5,538% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
29Shares Held
3.53MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$981,3826.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA529KShares$254,0870.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$175,9560.08% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$82,3130.0% of portfolio
-
Morgan Stanley New York, NY106KShares$50,9760.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $5.55M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...